Progress in neoadjuvant therapy for gastric cancer

被引：14

作者：

Su, Peng-Fei ^{[1
]}

Yu, Jian-Chun ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing 100730, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Medical Coll Hosp, Dept Gen Surg, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China

来源：

ONCOLOGY LETTERS | 2022年 / 23卷 / 06期

关键词：

gastric cancer; neoadjuvant chemotherapy; neoadjuvant chemoradiotherapy; targeted therapy; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; PHASE-III TRIAL; OPEN-LABEL; PERIOPERATIVE CHEMOTHERAPY; D2; GASTRECTOMY; PATHOLOGICAL RESPONSE; TUMOR-REGRESSION; INTERGROUP TRIAL; CHINESE PATIENTS; PLUS CISPLATIN;

D O I：

10.3892/ol.2022.13292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastric cancer is one of the most common malignant tumor types in the world and the majority of patients have already reached the advanced stage at the time of initial diagnosis, owing to the subtle symptoms of gastric cancer in the early stage and the low rate of screening in the population. Surgical resection is one of the main treatments for advanced gastric cancer; however, the efficacy of surgery is limited by factors such as low radical resection rate and high distant metastasis rate. A large number of clinical trials have indicated that neoadjuvant therapy (NAT), which consists of neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and NAT combined with targeted therapy, may improve the therapeutic effect and prognosis of patients to different degrees. However, the benefit of NAT remains controversial due to the heterogeneity of clinical trials and gastric cancer itself. The present review summarizes the main research progress and key breakthrough of NAT for advanced gastric cancer and discusses its prospects.

引用

页数：11

共 64 条

[1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[2] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Hofheinz, Ralf D. ;

Pauligk, Claudia ;

Kopp, Hans-Georg ;

Haag, Georg Martin ;

Luley, Kim Barbara ;

Meiler, Johannes ;

Homann, Nils ;

Lorenzen, Sylvie ;

Schmalenberg, Harald ;

Probst, Stephan ;

Koenigsmann, Michael ;

Egger, Matthias ;

Prasnikar, Nicole ;

Caca, Karel ;

Trojan, Joerg ;

Martens, Uwe M. ;

Block, Andreas ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Clemens, Michael ;

Illerhaus, Gerald ;

Zirlik, Katja ;

Behringer, Dirk M. ;

Schmiegel, Wolff ;

Pohl, Michael ;

Heike, Michael ;

Ronellenfitsch, Ulrich ;

Schuler, Martin ;

Bechstein, Wolf O. ;

Koenigsrainer, Alfred ;

Gaiser, Timo ;

Schirmacher, Peter ;

Hozaeel, Wael ;

Reichart, Alexander ;

Goetze, Thorsten O. ;

Sievert, Mark ;

Jaeger, Elke ;

Moenig, Stefan ;

Tannapfel, Andrea .

LANCET ONCOLOGY, 2016, 17 (12) :1697-1708

[3] Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial [J].

Alderson, Derek ;

Cunningham, David ;

Nankivell, Matthew ;

Blazeby, Jane M. ;

Griffin, S. Michael ;

Crellin, Adrian ;

Grabsch, Heike I. ;

Langer, Rupert ;

Pritchard, Susan ;

Okines, Alicia ;

Krysztopik, Richard ;

Coxon, Fareeda ;

Thompson, Joyce ;

Falk, Stephen ;

Robb, Clare ;

Stenning, Sally ;

Langley, Ruth E. .

LANCET ONCOLOGY, 2017, 18 (09) :1249-1260

[4]

Bang YJ, 2010, LANCET, V376, P1302

[5] Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].

Becker, K ;

Mueller, JD ;

Schulmacher, C ;

Ott, K ;

Fink, U ;

Busch, R ;

Böttcher, K ;

Siewert, JR ;

Höfler, H .

CANCER, 2003, 98 (07) :1521-1530

[6] Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas A Summary of 480 Cases [J].

Becker, Karen ;

Langer, Rupert ;

Reim, Daniel ;

Novotny, Alexander ;

zum Buschenfelde, Christian Meyer ;

Engel, Jutta ;

Friess, Helmut ;

Hofler, Heinz .

ANNALS OF SURGERY, 2011, 253 (05) :934-939

[7] Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy? [J].

Bozkaya, Yakup ;

Ozdemir, Nuriye Yildirim ;

Sezer, Sevilay ;

Kostek, Osman ;

Demirci, Nebi Serkan ;

Yazici, Ozan ;

Erdem, Gokmen Umut ;

Eren, Tulay ;

Zengin, Nurullah .

CANCER BIOMARKERS, 2018, 22 (01) :143-149

[8] Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial [J].

Cats, Annemieke ;

Jansen, Edwin P. M. ;

van Grieken, Nicole C. T. ;

Sikorska, Karolina ;

Lind, Pehr ;

Nordsmark, Marianne ;

Kranenbarg, Elma Meershoek-Klein ;

Boot, Henk ;

Trip, Anouk K. ;

Swellengrebel, H. A. Maurits ;

van Laarhoven, Hanneke W. M. ;

Putter, Hein ;

van Sandick, Johanna W. ;

Henegouwen, Mark I. van Berge ;

Hartgrink, Henk H. ;

van Tinteren, Harm ;

van de Velde, Cornelis J. H. ;

Verheij, Marcel .

LANCET ONCOLOGY, 2018, 19 (05) :616-628

[9] The changing face of gastric cancer: epidemiologic trends and advances in novel therapies [J].

Chandra, Raghav ;

Balachandar, Neeraja ;

Wang, Sam ;

Reznik, Scott ;

Zeh, Herbert ;

Porembka, Matthew .

CANCER GENE THERAPY, 2021, 28 (05) :390-399

[10] Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer [J].

Chen, Ruohua ;

Zhou, Xiang ;

Liu, Jianjun ;

Huang, Gang .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1040-1044

← 1 2 3 4 5 6 7 →